Premium
Distinctive molecular signaling in triple‐negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine)
Author(s) -
Chakrabandhu Krittalak,
Huault Sébastien,
Hueber Anne-Odile
Publication year - 2008
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2008.11.019
Subject(s) - miltefosine , triple negative breast cancer , apoptosis , cancer research , fas ligand , programmed cell death , breast cancer , cancer , chemistry , biology , medicine , immunology , biochemistry , leishmaniasis , visceral leishmaniasis
This study describes the molecular signaling involved in the different cell death modes of triple‐negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine. We found that the HePC treatment triggers cell‐type‐dependent apoptotic and non‐apoptotic cell death processes. Moreover, the expression level of the apoptosis activator Fas, and Fas/Fas ligand signaling capacity are not attributing factors for the preference toward apoptosis. Using Fas siRNA and overexpression approaches we establish that Fas is not a pro‐apoptotic factor but a contributor to cell protection in HePC‐apoptosis‐sensitive cells. The insight in the multi‐modal anticancer capability of HePC in triple‐negative breast cancer cells may facilitate the targeted design of therapeutic strategies against triple‐negative breast cancers.